Home > Publications database > ¹H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis. > print

001     309604
005     20260202155628.0
024 7 _ |a 10.1038/s41598-026-37118-5
|2 doi
024 7 _ |a pmid:41617901
|2 pmid
037 _ _ |a DKFZ-2026-00254
041 _ _ |a English
082 _ _ |a 600
100 1 _ |a Gellrich, Frank Friedrich
|0 0000-0002-2164-4644
|b 0
245 _ _ |a ¹H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis.
260 _ _ |a [London]
|c 2026
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1770044009_1634685
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #DKTKZFB9# / #NCTZFB9# / epub
520 _ _ |a Early detection of active melanoma metastasis is crucial. Serum metabolomics may offer non-invasive biomarkers, but real-world applicability needs validation. This study aimed to identify ¹H-NMR-based serum metabolic signatures for active metastasis in a large clinical cohort. Serum from 963 melanoma patients (1698 samples) underwent ¹H-NMR spectroscopy. Patients were classified by active metastasis status. OPLS-DA and RFE followed by logistic regression models were developed on a patient-level training/test split. Subgroup analyses assessed signatures related to Immune Checkpoint Inhibitor (ICI) therapy, brain metastases, and BRAF status. Models for active metastasis showed moderate test set discrimination (Area Under the Curve [AUCs]: OPLS-DA 0.609, RFE 0.630). The RFE-model highlighted seven significant metabolites: increased pyruvate, phenylalanine, acetoacetate, glutamate, glucose, and decreased histidine and citrate were associated with active metastasis. OPLS-DA yielded concordant metabolites. Subgroup analyses revealed distinct metabolic associations, e.g., for ICI therapy (citrate, RFE AUC 0.721) and BRAF status (acetate, RFE AUC 0.655), but limited performance for brain metastases (RFE AUC 0.553). ¹H-NMR serum metabolomics detects systemic metabolic alterations of active melanoma metastasis with moderate accuracy in a real-world setting. Identified disruptions in energy and amino acid metabolism offer pathobiological insights and warrant investigation for multimodal biomarker panels.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Biomarkers
|2 Other
650 _ 7 |a Melanoma
|2 Other
650 _ 7 |a Metabolic profiling
|2 Other
650 _ 7 |a Predictive model
|2 Other
650 _ 7 |a Tumor metabolism
|2 Other
700 1 _ |a Hufnagel, Cosima
|0 0009-0001-0859-2915
|b 1
700 1 _ |a Funk, Alexander M
|0 0000-0002-7248-4599
|b 2
700 1 _ |a Jonas, Sophie
|b 3
700 1 _ |a Altmann, Heidi
|0 P:(DE-He78)ad602776b59c10ecdda49cbb2d533cd4
|b 4
700 1 _ |a Hobelsberger, Sarah
|0 0000-0001-5703-324X
|b 5
700 1 _ |a Steininger, Julian
|0 0000-0001-9094-4512
|b 6
700 1 _ |a Feige, Christina
|b 7
700 1 _ |a Tasdogan, Alpaslan
|0 0000-0003-2543-852X
|b 8
700 1 _ |a Chavakis, Triantafyllos
|0 0000-0002-1869-5141
|b 9
700 1 _ |a Beissert, Stefan
|0 0000-0002-8327-8475
|b 10
700 1 _ |a Meier, Friedegund
|0 0000-0003-4340-9706
|b 11
700 1 _ |a Mirtschink, Peter
|0 0000-0001-5832-1673
|b 12
700 1 _ |a Steiner, Gerald
|0 0000-0002-7625-343X
|b 13
773 _ _ |a 10.1038/s41598-026-37118-5
|0 PERI:(DE-600)2615211-3
|p nn
|t Scientific reports
|v nn
|y 2026
|x 2045-2322
909 C O |p VDB
|o oai:inrepo02.dkfz.de:309604
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 0000-0002-2164-4644
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 0009-0001-0859-2915
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)ad602776b59c10ecdda49cbb2d533cd4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 0000-0001-5703-324X
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 0000-0001-9094-4512
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 0000-0003-2543-852X
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 0000-0003-4340-9706
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2026
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2022
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2025-08-21T14:09:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2025-08-21T14:09:21Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2025-08-21T14:09:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-07
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-07
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-11-07
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-07
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 0
920 1 _ |0 I:(DE-He78)DD04-20160331
|k DD04
|l Koordinierungsstelle NCT Dresden
|x 1
920 1 _ |0 I:(DE-He78)WT01-20160331
|k WT01
|l Koordinierungsstelle NCT West
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a I:(DE-He78)DD04-20160331
980 _ _ |a I:(DE-He78)WT01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21